CD4 and liver cancer: Collectively, these findings indicate that PPARα agonists cause liver cancer in mice through a mechanism that is associated with PPARα-dependent modulation of lipid metabolism including modest accumulation of linoleic acid, reduced hepatic CD4+ T cells, increased cellular senescence, and lowered serum cytokines.